

# **Central Lancashire Online Knowledge (CLoK)**

Title	Comparing hospital and telephone follow-up for patients treated for Stage I endometrial cancer 3 (ENDCAT Trial): a randomised, multicentre, non-inferiority trial
Type	Article
URL	https://clok.uclan.ac.uk/id/eprint/14040/
DOI	https://doi.org/10.1111/1471-0528.14000
Date	2017
Citation	Beaver, Kinta, Williamson, Susan, Sutton, Chris J, Hollingworth, William, Gardner, Anne, Allton, Barbara, Abdel-Aty, Mohamed, Blackwood, Karen, Burns, Sean et al (2017) Comparing hospital and telephone follow-up for patients treated for Stage I endometrial cancer 3 (ENDCAT Trial): a randomised, multicentre, non-inferiority trial. Bjog: An International Journal Of Obstetrics & Gynaecology, 124 (1). pp. 150-160. ISSN 1470-0328
Creators	Beaver, Kinta, Williamson, Susan, Sutton, Chris J, Hollingworth, William, Gardner, Anne, Allton, Barbara, Abdel-Aty, Mohamed, Blackwood, Karen, Burns, Sean, Curwen, Debbie, Ghani, Rauf, Keating, Patrick, Murray, Sandra, Tomlinson, Anne, Walker, Beverley, Willett, Mark, Wood, Nick and Martin-Hirsch, Pierre

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1111/1471-0528.14000

For information about Research at UCLan please go to <a href="http://www.uclan.ac.uk/research/">http://www.uclan.ac.uk/research/</a>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <a href="http://clok.uclan.ac.uk/policies/">http://clok.uclan.ac.uk/policies/</a>

1	Title Page
2	
3	Comparing hospital and telephone follow-up for patients treated for Stage I endometrial cancer
4	(ENDCAT Trial): a randomised, multicentre, non-inferiority trial
5	
6	Professor Kinta Beaver PhD
7	School of Health Sciences, University of Central Lancashire, Brook Building, Preston. PR1 2HE
8	Lancashire. UK
9	
10	Dr Susan Williamson PhD
11	School of Health Sciences, University of Central Lancashire, Brook Building, Preston. PR1 2HE
12	Lancashire. UK
13	
14	Dr Chris Sutton PhD
15	Lancashire Clinical Trials Unit, University of Central Lancashire, Brook Building, Preston. PR1 2HE
16	Lancashire. UK
17	
18	Professor William Hollingworth PhD
19	School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol
20	BS8 2PS
21	
22	Mrs Anne Gardner RGN
23	Women's Health Research Department, Lancashire Teaching Hospitals NHS Foundation Trust, Royal
24	Preston Hospital, Sharoe Green Lane, Fulwood, Preston. PR2 9HT

25 Ms Barbara Allton MSc 26 Department of Obstetrics & Gynaecology, University Hospitals of Morecambe Bay NHS Foundation 27 Trust, Royal Lancaster Infirmary, Ashton Road, Lancaster. LA1 4RP 28 29 Mr Mohamed Abdel-Aty FRCOG 30 Gynaecology Department, East Lancashire Hospitals NHS Trust, Burnley General Hospital, Casterton 31 Avenue, Burnley. BB10 2PQ 32 33 Ms Karen Blackwood RGN 34 Women's Healthcare Unit, Wrightington, Wigan & Leigh NHS Foundation Trust, Hanover Diagnostic and 35 Treatment Centre, Leigh Infirmary, The Avenue, Leigh, Wigan. WN7 1HS 36 37 Mr Sean Burns MRCOG 38 Women's Healthcare Unit, Wrightington, Wigan & Leigh NHS Foundation Trust, Hanover Diagnostic and 39 Treatment Centre, Leigh Infirmary, The Avenue, Leigh, Wigan. WN7 1HS 40 Ms Debbie Curwen RGN 41 42 Gynaecological Unit, Blackpool Teaching Hospitals NHS Foundation Trust, Whinney Heys Road, 43 Blackpool. FY3 8NR 44 Mr Rauf Ghani FRCOG 45 46 Department of Obstetrics & Gynaecology, University Hospitals of Morecambe Bay NHS Foundation 47 Trust, Royal Lancaster Infirmary, Ashton Road, Lancaster. Lancashire. LA1 4RP 48

49 **Dr Patrick Keating MBBS** 50 Women's Health Directorate, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston 51 Hospital, Sharoe Green Lane, Fulwood, Preston. PR2 9HT 52 53 Mrs Sandra Murray MSc 54 Women's Health Directorate, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston 55 Hospital, Sharoe Green Lane, Fulwood, Preston. PR2 9HT 56 57 Mrs Anne Tomlinson MSc 58 Corporate Cancer Team, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, 59 Sharoe Green Lane, Fulwood, Preston. PR2 9HT 60 61 Ms Beverley Walker BSc 62 Gynaecology Department, East Lancashire Hospitals NHS Trust, Burnley General Hospital, Casterton 63 Avenue, Burnley, East Lancashire. BB10 2PQ 64 Mr Mark Willett MRCOG 65 66 Gynaecology Department, East Lancashire Hospitals NHS Trust, Burnley General Hospital, Casterton 67 Avenue, Burnley, East Lancashire. BB10 2PQ 68 69 Dr Nick Wood MD 70 Women's Health Directorate, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston 71 Hospital, Sharoe Green Lane, Fulwood, Preston. PR2 9HT 72

73	Dr Pierre Martin-Hirsch MD
74	Women's Health Directorate, Lancashire Teaching Hospitals NHS Foundation Trust, Royal Prestor
75	Hospital, Sharoe Green Lane, Fulwood, Preston. PR2 9HT
76	
77	
78	Corresponding author:
79	Professor Kinta Beaver PhD
80	Professor of Cancer Care
81	School of Health Sciences
82	University of Central Lancashire
83	Brook Building
84	Preston. PR1 2HE
85	Lancashire. UK
86	E: kbeaver@uclan.ac.uk
87	T: 01772 893715; 07900 276105
88	
89	
90	Short running title:
91	
92	Telephone follow-up for endometrial cancer
93	

94 Comparing hospital and telephone follow-up for patients treated for Stage I endometrial cancer 95 (ENDCAT Trial): a randomised, multicentre, non-inferiority trial 96 97 **ABSTRACT** 98 Objective To evaluate the effectiveness of nurse-led telephone follow-up (TFU) for Stage I endometrial 99 cancer patients. 100 **Design** Multicentre, randomised, non-inferiority trial 101 **Setting** Five centres in the North West of England 102 Sample 259 women treated for Stage I endometrial cancer attending hospital outpatient clinics for 103 routine follow-up 104 Methods Participants were randomly allocated to receive traditional hospital based follow-up (HFU) or 105 nurse-led TFU. 106 Main outcome measures Primary outcomes were psychological morbidity (State Trait Anxiety Inventory, 107 STAI-S) and patient satisfaction with information. Secondary outcomes included patient satisfaction with 108 service, quality of life, and time to detection of recurrence. 109 Results STAI-S scores post-randomisation were similar between groups (mean [SD] TFU 33.0 [11·0], HFU 110 35.5 [13.0]). The estimated between group difference in STAI was 0.7 (95%CI -1.9 to 3.3); the CI lies 111 above the non-inferiority limit (-3·5) indicating non-inferiority of TFU. There was no significant difference 112 between groups in reported satisfaction with information (OR 0.9, 95% CI 0.4 to 2.1, p=0.83). The HFU 113 group were more likely to report being kept waiting for their appointment (p=0.001), that they did not 114 need any information (p=0.003) and were less likely to report that the nurse knew about their particular 115 case and situation (p=0.005).

116 Conclusions TFU provides an effective alternative to HFU for Stage I endometrial cancer patients, with 117 no reported physical or psychological detriment. Patient satisfaction with information was high, with 118 similar levels between groups 119 Keywords Endometrial cancer, telephone follow-up, gynaecology, oncology, patient satisfaction, 120 psychological morbidity 121 Word count: 239 122 123 **Trial Registration Number**: ISRCTN75220876. 124 125 Tweetable abstract (108 characters with spaces) 126 ENDCAT trial shows effectiveness of nurse-led telephone follow-up for Stage I endometrial cancer 127 patients.

#### **INTRODUCTION**

Most (75%) endometrial cancer patients present with Stage I disease (confined to the uterus); five year relative survival is over 70%. <sup>1,2</sup> More than 80% of all recurrences occur during the first three years. <sup>3</sup> Historically, patients in the United Kingdom (UK) have attended hospital outpatient appointments at regular but decreasing intervals for a period of three to five years. However, routine clinical review after gynaecology malignancy demonstrates little or no survival benefit; early detection of recurrence does not improve outcome or reduce morbidity. <sup>2–4</sup> A European study reported one asymptomatic recurrence for every 653 routine consultations. <sup>5</sup> Hence, there has been a call for prospective trials to evaluate alternative follow-up strategies for gynaecological cancers. <sup>4</sup>

UK Department of Health (DoH) guidance suggests that women treated for endometrial cancer should be informed about the lack of known benefit of follow-up, although retaining some degree of support post treatment.<sup>6</sup> The National Cancer Survivorship Initiative (NCSI) was key to the Cancer Reform Strategy,<sup>7</sup> aiming to improve services for cancer survivors in England and advocating supported self-management approaches to follow-up, accompanied by risk stratification (based on clinical and individual need).<sup>8</sup> Current follow-up practice does not meet cancer survivors' full range of needs <sup>8,9</sup> A recent rapid review of service provision following cancer treatment concluded that addressing the needs of cancer survivors, particularly with the predicted increase in numbers, requires new models of follow-up.<sup>10</sup> There are also increasing financial pressures to devise more efficient care pathways. Alternative strategies include nurse-led and supported self-management approaches. A systematic review of nurse-led versus conventional physician-led follow-up for patients with cancer concluded that patients are generally satisfied with nurse-led follow-up,<sup>11</sup> and a meta-analysis concluded that nurse-led telephone follow-up (TFU) services were acceptable, appropriate and effective. <sup>12</sup> Patients with early stage cancers at low risk of recurrence could be empowered to take responsibility for their care if sufficiently

supported, with rapid access back to secondary care if needed. Individual responsibility and self-management have been highlighted as central principles for successful implementation of the 2015-2020 strategy for improving cancer outcomes, empowering individuals to manage their own health care needs <sup>13</sup>. However, the NCSI reported that these models needed further testing and evaluation. The model we proposed for Stage I endometrial cancer follow-up built on previous studies of nurse-led TFU for breast and colorectal cancer patients, <sup>14–16</sup> demonstrating that specialist nurses can meet the information needs and concerns of people treated for cancer, with no physical or psychological detriment. We therefore designed a trial to test for non-inferiority of nurse-led TFU relative to traditional hospital based follow-up (HFU) following treatment for Stage I endometrial cancer.

#### **METHODS**

#### Study design and sample

We carried out a two group, parallel, multicentre randomised non-inferiority trial in five hospitals in North West England. Eligible patients had completed primary treatment for Stage I endometrial cancer and were returning to hospital outpatient clinics for routine monitoring. We excluded patients if they had hearing impairments or did not have access to a telephone. Patients were not excluded on the basis of language difficulties as this would need to be addressed regardless of study group allocation. Patient recruitment took place between 3<sup>rd</sup> January 2012 and 2<sup>nd</sup> January 2014.

### Randomisation and masking

Patients were randomly assigned (1:1) to HFU or TFU using a computer based system. Randomisation was performed using permuted blocks, with randomly varying block sizes, within 10 strata defined by the combinations of the five hospitals and follow-up duration (less than 1 year or 1 year or more post diagnosis). The trial statistician was masked to group allocation. It was not possible to mask clinical staff

or participants as they would have been aware that follow-up care was being delivered over the telephone or in hospital clinics.

#### Outcomes

Primary outcomes were psychological morbidity and patient satisfaction with information. Secondary outcomes included patient satisfaction with service, quality of life, and time to detection of recurrence. We assessed non-inferiority in terms of effectiveness (for psychological morbidity, quality of life, and time to detection of recurrence) and superiority in terms of patient satisfaction with information and service. Time to detection of recurrence was defined as the time from randomisation to the date when recurrence was communicated to the patient; we also report the time between the first indications of a suspicion of recurrence to the date when recurrence was communicated to the patient.

Psychological morbidity was measured using a standard instrument, the State Trait Anxiety Inventory (STAI).<sup>17,18</sup> Patient satisfaction with information and service was recorded using questionnaires adapted from previous work on breast cancer patients,<sup>14</sup> with the question used for the primary outcome being "Did you get all the information you needed at your hospital or telephone appointment?". Participants were asked about the frequency and duration of their appointments. Baseline and post-randomisation questionnaires contained similar questions although some questions were re-worded post-randomisation to reflect that patients could have had a hospital or telephone appointment. Quality of life was measured using the European Organization for Research and Treatment (EORTC) QLQ-C30 (version 3) and a specific module for endometrial cancer (QLQ-EN24).<sup>19,20</sup>

#### **Procedures**

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Potential participants were identified by clinical staff in hospital outpatient clinics. All participants completed baseline measures prior to randomisation. Patients allocated to HFU continued to receive hospital based follow-up as per hospital policy at the study locations. This consisted of appointments every three or four months for the first two years post treatment followed by appointments at decreasing intervals (six monthly and annually) up to a period of three to five years. At the end of this period, patients were discharged to the care of their General Practitioner (GP). Although there was no standard format to hospital based consultations, they would usually include a clinical examination (bimanual examination and inspection of the vagina) and questions about any signs of recurrent disease (e.g. vaginal bleeding, unusual discharge). In the TFU arm, a telephone intervention was administered by gynaecology oncology nurse specialists at intervals consistent with hospital policy at the study locations. At each study site, the frequency of delivery of the telephone intervention would mirror the frequency of scheduled hospital appointments for the control arm. Seven experienced gynaecology oncology nurse specialists administered the telephone intervention during the study period; these nurses had advanced practitioner roles with specialist knowledge and expertise in gynaecology. Patients were sent appointment cards with a date and time for their telephone appointments. The intervention was designed to be delivered in 20 minutes. Questions in the intervention were focused on physical, psychological and social aspects of care (Appendix S1). Training on the delivery of the intervention involved two half-day sessions, discussing issues related to telephone consultations, a detailed exploration of each intervention item and the practicalities of setting up telephone clinics.

219

220

221

222

All outcome data were collected at baseline (pre-randomisation) and immediately after the next HFU or TFU appointment (post-randomisation). The post-randomisation data collection time point depended on whether women were on a three monthly, six monthly or annual follow-up schedule. Hence, the post-

participants were sent postal questionnaires, once formal written consent had been received, and were asked to return the questionnaires in pre-paid envelopes to a university address. Careful attention was paid to ensuring questionnaires were dispatched immediately post consultation to ensure women's responses were targeted at the most recent hospital or telephone appointment. Introductory information on questionnaires instructed participants to refer to their 'most recent appointment'. Data on signs of recurrent disease were collected prospectively on 'record of clinic visit' and 'record of telephone consultation' proformas for all participants at all consultations throughout the study period. Participants' attendance at the next scheduled appointment (hospital or telephone) post-randomisation acted as a trigger for posting out the post-randomisation questionnaires to study participants. A full review of all participants' medical records was carried out at the end of the study follow-up period to ensure all pertinent data had been captured on the clinical proformas. Any indication of recurrent disease was monitored and tracked. Participants who were diagnosed with recurrence were withdrawn from intervention delivery and trial follow-up but their clinical trajectory was monitored. Hence, data on time to detection of recurrence could be reported.

#### Sample size

The sample size was based on a pre-stated margin of non-inferiority (3.5) for the intervention effect on the STAI-S and data (SD 10) from a previous trial of TFU for breast cancer patients. We planned for 80% power, a 5% significance level, and allowed for 20% attrition; the target sample size was 128 participants per group. For the co-primary outcome of 'satisfaction with information' it was calculated that this sample size would provide 80% power to detect an OR of at least 2.25 using ordinal regression techniques (5% significance level) based on control percentages of: 'very satisfied' 54%, 'satisfied' 39%

and 'not very satisfied' or 'very unsatisfied' 7%, approximate values from our previous trial; however the phrasing of the question was subsequently changed for use in ENDCAT. <sup>14</sup>

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

246

247

#### Statistical methods

Analysis was performed using SPSS (V 22) and Stata (V 13). Demographic and baseline characteristics were summarised using: mean (standard deviation), or median (inter-quartile range), as appropriate, if quantitative (continuous or count); median (inter-quartile range) or frequency (percentage), as appropriate, if ordinal; frequency (percentage) if categorical. Characteristics of participants and nonparticipants were compared using chi-square test or independent samples t-test, as appropriate. The primary statistical analysis of psychological morbidity (STAI S-anxiety) scores was based on an instrumental variables regression analysis using the intervention group factor as instrument, with participation/non-participation in the allocated follow-up appointment type at first follow-up as mediator (a 'complier-adjuster' causal analysis). This is the approach which was used in our previous breast cancer trial and enables comparison of findings between the two trials.<sup>14</sup> The model used also included the following baseline covariates to improve statistical efficiency: age, level of education and/or occupational group, hospital (randomisation stratum), follow-up duration (less than or at least one year post diagnosis at the time of recruitment), STAI S-anxiety, and STAI T-anxiety. Linear modelling, adjusting for the same set of factors, was used for a comparable analysis of the effect of intervention arm using 'as treated', 'as randomised' and 'per-protocol' (i.e. including only those who had their first post-randomisation appointment in line with the randomisation) populations. For the analysis of satisfaction with information received, ordinal logistic regression was used; those who did not need information were excluded, although a sensitivity analysis was performed to investigate the impact of handling this group differently (e.g. including them with those who reported that they got none of the

information they needed). Adjustment was for the same baseline factors as for the STAI-S, except the STAI measures were not included whereas the satisfaction with information was included.

Similar approaches were used for the following secondary outcome measures: linear modelling for overall satisfaction with service and ordinal logistic regression for satisfaction with individual aspects of service; logistic regression for patient information needs; instrumental variables regression for EORTC QLQ-C30 and EORTC QLQ-EN24 subscales. Adjustment used the same of baseline factors, but replacing the STAI measures with the baseline measure of the corresponding outcome. For satisfaction with individual aspects of service, the categories 'strongly agree' and 'agree' were merged, as were the categories 'strongly disagree' and 'disagree', due to sparse categories. For any categorical outcome measures, if categories remained sparse, Fisher's exact test was used (not adjusting for baseline factors). Inferential results are presented as 95% confidence intervals (CIs), with p-value when testing superiority; for testing, two-sided tests with a 5% significance level were used.

Exploratory subgroup analyses for the primary outcomes were performed by adding the relevant interaction terms to the model for the following pre-specified factors: routine follow-up interval at recruitment (<6 months vs  $\ge 6$  months); age (<70 vs  $\ge 70$ ); level of education (no qualification vs some qualification without degree vs degree); work status (actively working vs not actively working); occupational group. A p-value of <0.1 was deemed suggestive of a potential differential intervention effect across subgroups.

#### **RESULTS**

We recruited 259 participants; 129 were randomised to TFU and 130 to HFU (Figure 1). As patients had repeat visits in outpatient clinics, some patients declined consent on one occasion but asked to be

considered at subsequent appointments. It was challenging to obtain accurate data on the numbers of such individuals; some will have subsequently consented but many will have remained as 'pending'.

Figure 1 contains accurate data on number of appointments but, in attempting to avoid double counting, the number of known refusers (n=92) may reflect an under-estimate as it excludes any remaining as 'pending' or 'missed'. Nine randomised women did not have subsequent follow-up appointments (Figure 1) due to non-attendance (n=5), illness (n=2) and death (n=2).

#### Insert Figure 1 here

Participants were a median age of 65 years and a median of 12 months from diagnosis, with most (63%) on three or four month routine follow-up schedules; 51% were less than one year post surgery. Sociodemographic and treatment characteristics of the study sample are shown in Table 1. Seventy participants who were eligible for inclusion but refused participation were willing to provide sociodemographic details; non-participants were more likely to be from Black, Asian and Minority ethnic groups (p=0·019), not actively working (p=0·047), from non-skilled occupational classes (p=0·039), and had lower levels of education (p=0·060). The main reasons reported for non-participation included reassurance provided by clinical examinations, too soon after surgery and family members preferring patients to continue with HFU.

#### Insert Table 1 here

STAI-S scores at baseline (mean [SD] TFU 33.5 [11·3], HFU 35.9 [12.4]) were similar to scores post randomisation (mean [SD] TFU 33.0 [11·0], HFU 35.5 [13.0]). Using 'adjusted for treatment received' the estimated between group difference in STAI was 0·7 (95%CI -1·9 to 3·3); the CI lies above the non-inferiority limit (-3·5) indicating non-inferiority of TFU (Figure 2). Sensitivity analysis using alternative

'analysis sets' ('as treated', 'as randomised' and 'per protocol') all showed very similar results, supporting the conclusion of non-inferiority of TFU (Figure 2).

#### Insert Figure 2 here

There was no significant difference in reported satisfaction with information at the most recent appointment between groups (OR  $1\cdot1$ , 95% CI  $0\cdot5$  to  $2\cdot4$ , p=0·89), with 75/96 (78%) of the TFU group and 62/78 (79%) of the HFU group who expressed an opinion reporting that they got all the information they needed (Table S1). However, more participants in the HFU group than the TFU group (27·8% vs.  $13\cdot5\%$ ) stated that they did not need any information (p=0·003) and, when a sensitivity analysis was performed including these as 'got none of the information I needed', this showed a significant between-groups difference in reported satisfaction with information at the most recent appointment (OR  $2\cdot0$ , 95% CI  $1\cdot1$  to  $3\cdot5$ , p=0·019).

Regardless of group allocation, participants were highly satisfied with the service they had received and there were no significant differences between groups (mean [SD] TFU  $9\cdot2$  [ $1\cdot5$ ], HFU  $8\cdot9$  [ $1\cdot7$ ], p=0·58, 95%Cl adjusted mean difference -0·5 to 0·3). Overall, participants considered that their appointments had been 'about right' in terms of both frequency and duration, with no significant differences between randomised groups (p=0·76 for frequency, p=0·20 for duration). Participants in the HFU arm were more likely to indicate that they had been kept waiting for their appointments (p=0·001). Participants in the TFU arm were more likely to indicate that the person they spoke to paid attention to what they were saying (p=0·042), that they could express themselves and ask questions (p=0·016) and that the person they spoke to knew about their particular case (p=0·005) (Table 2). Information needs did not differ

significantly between groups for any item (Table 3). Overall, information about familial risk, self-care, and sexual attractiveness and sexual function were the most prevalent information needs reported.

Insert Table 2 here

Insert Table 3 here

There were no significant differences between groups for quality of life in relation to the EORTC QLQ-C30. Only one single item showed between group differences with participants in the HFU arm more likely to report problems with constipation (p=0·035) (Table S2). For the QLQ-EN24 there were no significant differences between groups (Table S3).

Ten (4%) participants, five in each group, had a recurrence during the study period; one participant in each group died as a result of their cancer. Seven recurrences were distant; three in the TFU group and four in the HFU group. All recurrences were symptomatic. Symptoms included abdominal pain/swelling (n=6), vaginal bleeding (n=3) and back pain (n=1). All recurrences presented as interval events, with patients presenting symptoms to their GP (n=6) or contacting a nurse specialist (n=4) between scheduled appointments. The times from randomisation to diagnosis of recurrence were variable but not dissimilar in both groups (TFU median 307 days, range 48-662 days; HFU 172 days, 99-436 days) and the corresponding times from reporting symptoms (TFU median seven days, range 3-18 days; HFU nine days 3-70 days) were also not dissimilar.

For the five planned subgroup analyses on the two primary outcomes, there was no significant subgroup effect on the STAI, nor on satisfaction with information received except work status at recruitment (p=0.080; OR 4.92, 95%CI 0.83 to 29.3). This suggested that those in work in the HFU arm were relatively

less satisfied with information received than those in work in the TFU arm but this pattern was not observed amongst those not working.

#### DISCUSSION

#### **Main Findings**

The results of the ENDCAT trial were similar to those of a previous breast cancer trial and colorectal cancer pilot trial that used the same primary outcome measures. <sup>14,16</sup> The ENDCAT study findings indicate that specialist nurses are able to deliver a follow-up service over the telephone for Stage I endometrial cancer patients; TFU was non-inferior to HFU. Hence, nurse-led TFU can replace, or complement, doctor-led HFU without increasing patient anxiety or reducing overall satisfaction with information and service. Furthermore, there was evidence that participants preferred the TFU process as telephone appointments were more likely to be on time and patients felt more able to express themselves and ask more questions. There was no evidence to suggest that diagnosis of recurrence was delayed by TFU. Although recurrences were few (n=10), as would be expected in a low risk group, none of the recurrences were detected by clinical examination of asymptomatic patients; all recurrences were symptomatic and interval events.

## **Strengths and Limitations**

Our study is the only trial of nurse-led telephone follow-up for endometrial cancer patients that has been published to date. The study was conducted in the North West of England, although we see no reason why the findings should not be generalisable to other NHS regions. The geographical locations were diverse in terms of populations and ethnic diversity, although this was not represented in the sample, which was predominantly white British. Although ethnic group was associated with refusal to participate, numbers of eligible women from minority ethnic groups was low overall. This may reflect a

more international problem of under-representation of minority groups in cancer clinical trials<sup>21, 22</sup>. Although more white women are diagnosed with endometrial cancer in England than other ethnic minority groups, age standardised incidence rates are similar for white and South Asian women and are higher for black and Chinese women<sup>23</sup>. Hence, the low numbers of women from ethnic minority groups eligible for recruitment cannot be readily explained and can be considered a limitation. For practical reasons, and limitations to the funding period, it was not possible to recruit all participants immediately after their first post-treatment outpatient appointment. Although 51% of women were less than one year post surgery, many would have experienced a number of hospital outpatient appointments and this may have biased outcomes. Given that women would have experienced at least one hospital appointment prior to recruitment it is not possible to state when the introduction of TFU would be most beneficial or if the findings are generalisable to the first follow-up appointment. There may also have been a carry-over effect with participants reporting on a change of appointment type rather than reporting purely on telephone follow-up

#### Interpretation

On an international level, nurse-led and TFU approaches are increasingly advocated. A recent survey in South West England indicated that nurse-led TFU had similar levels of patient satisfaction to conventional doctor-led follow-up, <sup>24</sup> providing further support for a shift away from traditional approaches. It may not be practical to suggest that all patients with early stage endometrial cancer are followed up post treatment by specialist nurses. Resource limitations and workloads may inhibit broad implementation. However, we now have increasing evidence that TFU is non-inferior to HFU and patients could be offered a choice of follow-up regime. In this study we mirrored the frequency of hospital appointments to enhance research rigour. In clinical practice it may be that appointment frequency can be negotiated with patients based on their preferences and patients may benefit from

more flexible approaches to follow-up care. Patients may prefer one or two hospital appointments before TFU is implemented and further research is needed to determine the most appropriate time points at which to implement TFU.

Busy hospital clinics and ever increasing numbers of cancer survivors indicate that historical practices need to change and nurse-led TFU may not go far enough in addressing the challenge of meeting the needs of millions of cancer survivors within limited resources. Self-management approaches, where patients are discharged back to primary care on completion of treatment, may become standard practice in the future for low risk groups. There may be a sense of urgency to implement new approaches but it is vital that we have the evidence to support these implementation decisions. A recent survey on gynaecology follow-up practices in the UK found that 98% of 117 respondents indicated that regular scheduled hospital follow-up was the approach most commonly implemented. A small minority reported using nurse-led and telephone approaches with none reporting GP led follow-up practices. Providing the evidence that TFU is a non-inferior service could give providers and commissioners confidence to implement effective approaches while more novel approaches are being evaluated for quality and safety.

The recent strategy document for improving cancer outcomes in England over the next five years (2015-2020) argues that stratified follow-up pathways that promote self-management offer a more effective approach to follow-up than traditional medical models of follow-up<sup>13</sup>. Positive patient experience is paramount and nurse specialists have been reported as the most important contributors to positive patient experience and yet this workforce is not expanding to keep pace with the growing numbers of cancer survivors. While TFU is an acceptable alternative to hospital based approaches it still has workforce and cost implications. In 2006 it was reported that a study called FIGURE would investigate

patient initiated follow-up for endometrial cancer patients<sup>26</sup> but this trial did not open for recruitment. There are trials underway in Europe exploring more minimalist approaches to endometrial cancer follow-up. The TOTEM trial (Italy) compares different intensity follow-up regimes in two groups: minimalist (reduced schedule of clinic visits with gynaecological examination and limited investigations - chest, abdomen, pelvis CT every 12 months in minimalist/high risk group) versus intensive (regular clinic visits with gynaecological examination and regular investigations - pap tests, Ca125, trans-vaginal and abdominal ultrasound, and chest, abdomen, pelvis CT) based on risk of relapse (high versus low risk) with overall survival as the primary outcome measure (Clinical Trials Identifier: NCT00916708). The OPAL trial (Denmark) compares hospital based follow-up (including clinical examination) with a minimalist approach (patient self-referral and instruction on alarm signals that warrant contact with a health care professional with fear of recurrence as the primary outcome (Clinical Trials Identifier: NCT01853865)). As minimalist approaches gain momentum, TFU and HFU may both be considered suitable control arms for studies that investigate novel approaches to follow-up that effectively meet patient's needs and provide positive experiences of care within constrained health care budgets.

#### Conclusion

ENDCAT demonstrates that nurse-led TFU can effectively replace doctor-led HFU for the routine followup of patients treated for Stage I endometrial cancer. Patients reported greater satisfaction with some aspects of the process and content of their follow up appointment.

#### Acknowledgements

We would like to thank all the patients who took part in the study. Administrative support was provided by Simone Finley with statistical support for data entry and supervised analysis provided by Jane Burnell

459 and Laura Howell. Thanks are expressed to Bill Ryder who chaired the independent Trial Steering Group 460 for the study duration. 461 **Disclosure of Interests** No conflicts of interest declared. 462 463 464 Contribution to authorship 465 PMH and KB conceived the study. All authors contributed to the overall design of the study. MA, SB, RG, 466 PK, PMH, MW and NW treated patients and liaised with treating centres. BA, KB, DC, SM, AT, and BW 467 delivered the telephone intervention. AG provided overall trial management. AG, SW and KB recruited 468 patients to the study. CJS and WH had responsibility for data analysis. All authors had a role in 469 interpreting data. KB and CJS wrote the first draft of the manuscript. All authors contributed to 470 subsequent revisions and approved the final draft for submission. 471 **Details of ethical approval** 472 All patients provided written consent before registration in the trial. Ethical approval was granted by the 473 National Research Ethics Service (11/NW/0648) on 3<sup>rd</sup> October 2011 and approval from the Research & 474 475 Development departments of all participating centres was obtained prior to recruitment. 476 477 **Funding** 478 This paper presents independent research funded by the National Institute for Health Research (NIHR)

under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0610-22123).

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the

Department of Health. The funder had no role in study design, data collection, data analysis, data

479

480

481

21

interpretation, or writing the report. The corresponding author had full access to all the data collected for the study and had final responsibility for the decision to submit the manuscript.

# 486 **REFERENCES** 487 1. Cancer Research UK. Uterus (womb) cancer – UK incidence statistics 488 http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-489 type/uterine-cancer/survival#heading-Zero. (accessed Nov 4, 2015) 490 491 2. Baekelandt MM, Castiglione M, on behalf of the ESMO Guidelines Working Group. Endometrial 492 carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 493 20(supplement 4): iv29-31 494 495 3. Tjalma WAA, Van Dam PA, Markar AP, Cruikshank DJ. The clinical value and the cost-effectiveness of 496 follow-up in endometrial cancer patients. Int J Gynecol Cancer 2004; 14(5): 931–37. 497 498 4. Kew FM, Roberts AP, Cruickshank DJ (2005). The role of routine follow-up after gynaecological 499 malignancy. Int J Gynecol Cancer 2005; 15(3): 413-19 500 501 5. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of 502 routine follow-up. Br J Obstet Gynaecol 1997; 104 (11): 1302-07 503 504 6. Department of Health. Guidance on Commissioning Cancer Services: Improving Outcomes in 505 Gynaecological Cancers, 1999. Department of Health; London 506 7. Department of Health. Cancer Reform Strategy, 2007. Department of Health; London 507 508

509	8. Department of Health. National Cancer Survivorship Initiative Vision, 2010. Department of Health and
510	Macmillan Cancer Support; London, UK
511	
512	9. Macmillan Cancer Support. Two Million Reasons: The Cancer Survivorship Agenda, 2008. Macmillan
513	Cancer Support; London
514	
515	10. NHS Improvement. Rapid review of current service provision following cancer treatment, 2010. NHS
516	Improvement; Leicester, UK
517	
518	11. Lewis R, Neal RD, Williams NH, France B, Wilkinson C, Hendry M et al. Nurse-led vs. conventional
519	physician led follow-up for patients with cancer: systematic review. J Adv Nurs 2009; 65(4): 706–23.
520	
521	12. Cox K, Wilson E (2003). Follow-up for people with cancer: nurse-led services and telephone
522	interventions. <i>J Adv Nurs</i> 2003; 43(1): 51–61
523	
524	13. Independent Cancer Taskforce. Achieving world class cancer outcomes: a strategy for England 2015-
525	2020. http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes
526	_a_strategy_for_england_2015-2020.pdf
527	
528	14. Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A et al. Comparing
529	hospital and telephone follow-up after treatment for breast cancer: a randomised equivalence trial. BM.
530	2009; 338: a3147
531	

532 15. Beaver K, Hollingworth W, McDonald R, Dunn G, Tysver-Robinson D, Thomson L et al. Economic 533 evaluation of hospital versus telephone follow-up after treatment for breast cancer: evidence from a 534 randomized trial. Br J Surg 2009; 96: 1406–15 535 536 16. Beaver K, Campbell M, Williamson S, Procter S, Sheridan J, Heath J, Susnerwala S. An exploratory trial 537 comparing telephone and hospital follow-up after treatment for colorectal cancer. Colorectal Dis 2012; 538 14: 1201-09 539 540 17. Spielberger CD. State-Trait Anxiety Inventory 1983 Consulting Psychologists Press Inc. 541 542 18. Bowling A. Measuring Disease. 2nd Edition. 2001 Open University Press; Buckingham 543 544 19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization 545 for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international 546 clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76 547 548 20. Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB et al. Psychometric 549 validation of the European Organisation for the Research and Treatment of Cancer Quality of Life 550 Questionnaire – Endometrial Cancer Module (EORTC QLQ EN24). Eur J Cancer 2011; 47: 183–90 551 552 21. Chen MS, Lara PN, Dang JHT, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: 553 Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving 554 minority clinical trial accrual. Cancer 2014; 120(7 suppl): 1091-96

555

556	22. Symonds RP, Lord K, Mitchell AJ, Raghavan D. Recruitment of ethnic minorities into cancer clinical
557	trials: experience from the front lines. Br J Cancer 2012; 107: 1017–21
558	
559	23. Shirley MH, Barnes I, Sayeed S, Ali R. Incidence of breast and gynaecological cancers by ethnic group
560	in England, 2001-2007: a descriptive study. BMC Cancer 2014; 14:979
561	
562	24. Smits A, Lopes A, Das N, Bekkers R, Kent E, McCullough Z, Galaal K. Nurse-led telephone follow-up:
563	improving options for women with endometrial cancer. Cancer Nurs 2014; 38: 232–38
564	
565	25. Leeson S, Stuart N, Sylvestre Y, Hall L, Whitaker R. Gynaecological cancer follow-up: national survey
566	of current practice in the UK. BMJ Open 2013; 3:e002859
567	
568	26. Nordin AJ (on behalf of the National Group of Gynaecology NSSG Leads). Mode of detection of
569	recurrent gynecological malignancy: does routine follow-up delay diagnosis and treatment? Int J Gynecol
570	Cancer 2006; 16:1746–48.

Figure 1. Trial Flow




Table 1. Characteristics of the study sample. Data are n (%) unless otherwise stated.

	Total (n=259)	TFU (n=129)	HFU (n=130)
Age at recruitment			
Median (IQR)	65 (58 to 71)	66 (60 to 72·5)	64 (57·8 to 69)
Marital Status			
Married / co-habiting/civil	195 (75.3%)	95 (73.6%)	100 (76.9%)
partnership			
Divorced / separated	17 (6.6%)	8 (6.2%)	9 (6.9%)
Widowed	31 (12.0%)	16 (12-4%)	15 (11.5%)
Never married	16 (6.2%)	10 (7.8%)	6 (4.6%)
<b>Educational Level</b>			
No Formal Qualifications	43 (16.7%)	21 (16.4%)	22 (16.9%)
O-Levels, A-Levels,	201 (77.9%)	99 (77.3%)	102 (78.5%)
Vocational and			
Certificate/Diplomas			
Degree and above	14 (5.4%)	8 (6.3%)	6 (4.6%)
<b>Current Employment Status</b>			
Currently Working	97 (37.5%)	43 (33.3%)	54 (41.5%)
Not Currently Working	162 (62.5%)	86 (66.7%)	76 (58·5%)
Occupational Classification			
Managers, Directors and	19 (7.6%)	9 (7.2%)	10 (8.0%)
Senior Officials			
Professional Occupations	60 (24.0%)	31 (24.8%)	29 (23·2%)
Associate Professional and	12 (4.8%)	10 (8.0%)	2 (1.6%)
Technical Occupations			
Administrative and Secretarial	54 (21.6%)	25 (20.0%)	29 (23·2%)
Occupations			
Skilled Trades Occupations	15 (6.0%)	6 (4.8%)	9 (7.2%)
Caring, Leisure and Other	38 (15.2%)	20 (16.0%)	18 (14.4%)
Service Occupations			
Sales and Customer Service	17 (6.8%)	11 (8.8%)	6 (4.8%)
Occupations			
Process, Plant and Machine	5 (2.0%)	2 (1.6%)	3 (2.4%)
Operatives			
Elementary Occupations	30 (12.0%)	11 (8.8%)	19 (15·2%)
Ethnic group			
White British	256 (98.8%)	128 (99-2%)	128 (98.5%)
Indian	2 (0.8%)	1 (0.8%)	1 (0.8%)
Polish	1 (0.4%)	0 (0.0%)	1 (0.8%)
Type of surgery received			
Abdominal Hysterectomy	195 (75-3%)	97 (75·2%)	98 (75.4%)
Vaginal Hysterectomy	7 (2.7%)	6 (4.7%)	1 (0.8%)
Keyhole Surgery (LAVH)	46 (17.8%)	19 (14.7%)	27 (20.8%)
Hysterectomy - type unknown	11 (4.2%)	7 (5.4%)	4 (3.1%)
Received Radiotherapy			
Yes	11 (4.2%)	6 (4.7%)	5 (3.8%)
Time from diagnosis			
Median (IQR) (months)	12 (4 to 24)	12 (3.5 to 22)	12 (4 to 26)
Follow-up status at Recruitment	t		
3-4 months	163 (62.9%)	81 (62.8%)	82 (63·1%)
6 months	82 (31.7%)	44 (34·1%)	38 (29·2%)
12 months	14 (5.4%)	4 (3.1%)	10 (7.7%)
12 mondo	17 (3.770)	Ŧ (3·1/0)	10 (7-770)

Table 2. Satisfaction with aspects of service provision at follow-up by randomised group

		TFU			HFU		р
	Strongly Disagree/Disagree	Neither agree or disagree	Strongly Agree/Agree	Strongly Disagree/Disagree	Neither agree or disagree	Strongly Agree/Agree	
I was kept waiting too long for my	87 (83.7%)	12 (11.5%)	5 (4.8%)	82 (73.9%)	5 (4.5%)	24 (21.6%)	0.001
appointment							
The person I saw was able to deal with any problems I had	4 (3.6%)	5 (4.5%)	101 (91.8%)	4 (3.7%)	8 (7.3%)	97 (89.0%)	0.48
The person I spoke to told me all I wanted to know	2 (1.8%)	5 (4.4%)	107 (93.9%)	4 (3.6%)	8 (7.3%)	98 (89.0%)	0.26
I was not given enough information about my medication (tablets) and the side effects	21 (72·4%)	5 (17-2%)	3 (10·3%)	33 (68-8%)	12 (25.0%)	3 (6.3%)	0.88
The person I spoke to took no interest in me as a person	104 (91·2%)	3 (2.6%)	7 (6.1%)	96 (86.5%)	6 (5.4%)	9 (8.1%)	0.25
The person I spoke to gave me a chance to say what was really on my mind	2 (1.8%)	4 (3.5%)	107 (94·7%)	7 (6.5%)	6 (5.6%)	94 (87·9%)	0.07
The person I spoke to paid attention to what I was saying	2 (1.7%)	2 (1.7%)	111 (96.5%)	4 (3.5%)	7 (6.2%)	102 (90·3%)	0.042
I felt able to express myself and ask questions	0 (0.0%)	4 (3.5%)	110 (96.5%)	6 (5.4%)	6 (5.4%)	99 (89·2%)	0.016
after talking to the doctor/nurse I felt much better about my problems	1 (0.9%)	18 (17.0%)	87 (82·1%)	5 (5.0%)	23 (22·8%)	73 (72·3%)	0.66
The person I spoke to did not spend enough time talking to me	103 (91·2%)	5 (4.4%)	5 (4.4%)	99 (87.6%)	8 (7.1%)	6 (5.3%)	0.40
The person I spoke to really seemed to know about my particular case and situation	2 (1.8%)	12 (10.5%)	100 (87.7%)	13 (11.7%)	16 (14-4%)	82 (73.9%)	0.005
The person I spoke to investigated any problems I mentioned to my satisfaction	1 (1.0%)	17 (16·5%)	85 (82·5%)	5 (5·3%)	18 (19·1%)	71 (75.5%)	0.17

Table 3. Information needs at follow-up by randomised group. \* P-values from Fisher's exact test reported due to low cell frequencies.

	TFU		Н	FU	
	Yes	No	Yes	No	P
Q17: Information about the cancer diagnosis?	6 (5.3%)	108 (94.7%)	4 (3.5%)	110 (96.5%)	0.75*
Q18: Information about the different types of treatment, including side	2 (18%)	109 (98-2%)	1 (0.9%)	110 (99·1%)	1.0*
effects? (e.g. surgery, chemotherapy, radiotherapy					
Q19: Information about whether your children or other members of the	16 (14.3%)	96 (85.7%)	31 (27.7%)	81 (72·3%)	0.10
family are at risk of getting endometrial (womb) cancer?					
Q20: Information about how the treatment may have affected your feelings	7 (6.3%)	105 (93.8%)	12 (10.8%)	99 (89-2%)	0.80
about your body, your sexual attractiveness and sexual function					
Q21: Information about caring for yourself? (e.g. diet, support groups,	10 (8.8%)	103 (91.2%)	14 (12.4%)	99 (87.6%)	0.12
finances, psychological support)					
Q22: Have you had any concerns about how your family are coping with	4 (3.5%)	110 (96.5%)	5 (4.5%)	106 (95.5%)	0.30
your diagnosis					
Q23: Do you need information about anything else not mentioned in	1 (0.9%)	111 (99·1%)	2 (1.8%)	111 (98-2%)	1.0*
questions 17-22?					

Table S1. Satisfaction with information received post-randomisation by randomised group

	TOTAL	TFU	HFU
	(n=219)	(n=111)	(n=108)
I got all the information I needed	137 (62.6%)	75 (67-6%)	62 (57·4%)
I got most of the information I needed	30 (13·7%)	20 (18·0%)	10 (9·3%)
I got some of the information I needed	6 (2.7%)	1 (0.9%)	5 (4.6%)
I got none of the information I needed	1 (0.5%)	0 (0.0%)	1 (0.9%)
I did not need any information	45 (20·5%)	15 (13.5%)	30 (27.8%)

# Table S2 EORTC QLQ-C30 subscales by randomised group.

\* Hospital group mean minus telephone group mean, adjusted for age, level of education, occupational group, centre, baseline EORTC C30 score and post-operative follow-up status (<1 year; ≥1 year).

	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Р	Adjusted mean
	Baseline	Telephone	Hospital clinic	Telephone group	Hospital clinic		difference (95% CI) *
	Total	group	group	First Post-	group		
		Baseline	Baseline	randomisation	First Post-		
				Appointment	randomisation		
					Appointment		
Global health status QoL (revised)	72.9 (19.8)	72.8 (20.0)	73.0 (19.8)	71.6 (19.8)	73·2 (21·5)	0.31	2·1 (-2·0 to 6·2)
Physical functioning (revised)	76·1 (25·3)	73.6 (27.0)	78·5 (23·3)	76·5 (24·3)	78.5 (24.9)	0.50	-1·3 (-5·0 to 2·4)
Role functioning (revised)	75.5 (32.2)	72·5 (33·2)	78·5 (31·0)	76.9 (32.6)	82.0 (29.4)	0.44	2·4 (-3·7 to 8·4)
Emotional functioning	83.3 (19.7)	85·3 (18·2)	81.4 (21.0)	84.6 (19.5)	80.8 (24.0)	0.73	0·8 (-3·7 to 5·3)
Cognitive functioning	84.6 (19.6)	84.6 (20.3)	84.7 (19.0)	87.0 (16.0)	83.8 (21.4)	0.41	-1·5 (-5·1 to 2·1)
Social functioning	83.2 (26.8)	83·1 (27·0)	83.3 (26.8)	86.6 (24.7)	85·1 (26·0)	0.82	-0·6 (-6·1 to 4·8)
Fatigue	27.9 (24.0)	29.6 (25.7)	26.2 (22.3)	29·2 (28·3)	24.9 (25.7)	0.23	-3·2 (-8·4 to 2·0)
Nausea and vomiting	3.6 (11.4)	2.4 (10.6)	4.7 (12.1)	3.5 (9.7)	4.6 (12.8)	0.83	0·3 (-2·6 to 3·2)
Pain	21.4 (28.8)	21.3 (28.8)	21.5 (29.0)	21.5 (29.8)	20.1 (30.1)	0.56	-1·8 (-7·8 to 4·3)
Dyspnoea	14.6 (22.8)	16.4 (24.3)	12.9 (21.1)	17.5 (28.5)	13.2 (23.7)	0.50	-1·9 (-7·4 to 3·6)
Insomnia	32·1 (32·2)	31.4 (31.7)	32.8 (32.8)	27.3 (31.1)	32.2 (31.8)	0.26	3·5 (-2·5 to 9·5)
Appetite loss	7.3 (17.8)	7.3 (17.9)	7.2 (17.8)	4.4 (11.3)	4.2 (13.5)	0.60	-0·8 (-3·9 to 2·2)
Constipation	14.8 (25.8)	13·1 (24·1)	16.5 (27.3)	10.4 (20.9)	15.9 (25.2)	0.035	5·0 (0·4 to 9·6)
Diarrhoea	5.9 (17.0)	4.1 (13.9)	7.7 (19.5)	3.2 (9.9)	4.4 (13.0)	0.98	0 (-2·7 to 2·8)
Financial difficulties	7.5 (20.1)	5.0 (14.7)	10.0 (24.0)	4.7 (13.9)	6.5 (20.1)	0.31	-1·8 (-5·3 to 1·7)

Table S3. EORTC QLQ-EN24 subscales by randomised group.

\* Hospital group mean minus telephone group mean, adjusted for age, level of education, occupational group, centre, baseline EORTC score and post-operative follow-up status (<1 year; ≥1 year).

	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Р	Adjusted mean
	Baseline	Telephone	Hospital clinic	Telephone group	Hospital clinic		difference (95% CI) *
	Total	group Baseline	group Baseline	First Post- randomisation	group First Post-		
		Daseille	Daseille	Appointment	randomisation		
				Appointment	Appointment		
Sexual interest	17.5 (25.0)	14.5 (24.6)	20.5 (25.0)	16.7 (24.6)	21.4 (24.6)	0.41	-2·1 (-7·0 to 2·9)
Sexual activity	12.8 (21.6)	12·2 (21·8)	13·3 (21·5)	13·1 (24·3)	18.0 (23.6)	0.13	4·0 (-1·1 to 9·0)
Sexual enjoyment	53·3 (34·3)	51·3 (35·6)	54.9 (33.7)	56.8 (31.8)	61.0 (29.7)	0.20	-7·4 (-18·7 to 3·9)
Lymphoedema	14.2 (23.5)	17.8 (25.3)	10.6 (21.0)	16.8 (23.7)	11.4 (20.2)	0.47	-1·6 (-6·0 to 2·8)
Urological symptoms	22.4 (21.1)	23.3 (22.2)	21.6 (20.1)	20.4 (22.0)	18.4 (18.6)	0.64	-0·9 (-4·9 to 3·0)
Gastrointestinal	14.5 (17.0)	15.0 (17.7)	14.0 (16.4)	11.3 (12.9)	11.1 (14.6)	0⋅58	0·8 (-2·0 to 3·5)
symptoms							
Body image problems	13·1 (25·4)	11.6 (23.5)	14.7 (27.2)	8.0 (16.9)	11.5 (25.3)	0.35	1·9 (-2·1 to 5·9)
Sexual/vaginal problems	32.4 (29.8)	32.5 (29.8)	32.4 (30.3)	25.9 (28.7)	24.7 (30.8)	0.37	5·0 (-6·0 to 15·9)
Back/pelvis pain	28.0 (31.3)	27·2 (29·7)	28.8 (32.7)	27·1 (32·1)	24.8 (31.4)	0.13	-4·9 (-11·2 to 1·4)
Tingling/numbness	15·1 (25·3)	15.9 (27·2)	14.4 (23.4)	16.2 (26.8)	12.6 (21.9)	0.31	-2·8 (-8·2 to 2·6)
Muscular pain	37-2 (32-8)	37.4 (31.7)	36.9 (34.0)	36.6 (33·2)	31.3 (30·8)	0.11	-5·7 (-12·7 to 1·3)
Hair loss	4.5 (14.9)	5.2 (16·6)	3.8 (12.9)	5.3 (15·1)	5.3 (14·4)	0.60	0·9 (-2·6 to 4·5)
Taste change	5.6 (16.3)	6.9 (19·2)	4.3 (12·7)	3.2 (11·7)	1.5 (6.9)	0.29	-1·4 (-3·9 to 1·2)

Note: EORTC QLQ-C30 and QLQ-EN24 have both function and symptom subscales. For function subscales a higher score indicates a better performance in this subscale, so a positive difference in means implies a higher function in the hospital group. For symptom subscales a higher score indicates a higher level of symptoms in this subscale, so a positive difference in means implies a higher level of this symptom in the hospital group.



## **TELEPHONE INTERVENTION (ENDCAT TRIAL)**

# Questions to be asked by Gynaecology Oncology Clinical Nurse Specialist (CNS) at telephone consultation

\*nb Please re-check patient consent for audio recording\*

Patient Name:
Hospital Number:
Date of Birth:
CNS Initials:
Date:
Follow-up telephone call (please tick)
3 months 4 months 6 months 12 months
Other (please state)
Hello, this is <name nurse="" of="" specialist=""> phoning for our month follow-up appointment</name>
1. How are you doing with (issues related to previous hospital visit/telephone appointment)?
CNS - please tick one box
Issues remain a problem Issues partly resolved
Issues fully resolved No problems recorded

2.	Since your last follow-up appointment has anything changed?			
	Yes No No			
	If yes, what has changed?			
	CNS – If yes, was this change in condition addressed over the phone?			
	Yes (fully) Yes (partly) No			
	Was further action indicated? Yes No			
	If yes, what was the course of action?			
3.	Since your last appointment have you noticed any of the following:			
	• Bleeding Yes No			
	Unusual discharge Yes No			
	Unusual aches and pains     Yes     No			
CNS – if yes to any of the above what was the course of action indicated?				

I have a list of things that other people have said they'd like to have information about following treatment. Obviously, not all of them will apply to you, but do you mind if we work through the list anyway and you can tell me if you need information (or have any concerns) about any of these areas?

4.	. Do you need information about the operation you had?		
	Yes No		
	CNS - If yes, what information was needed?		
	If yes, was the information need met over the phone?		
	Yes (fully) Yes (partly) No		
	Was further action indicated? Yes No		
	If yes, what was the course of action?		
5. Do you need more information about your cancer diagnosis?			
	Yes No		
	CNS - If yes, what information was needed?		
	If yes, was the information need met over the phone?		
	Yes (fully) Yes (partly) No		

If applicable. Do you need in including side effects (i.e. ch		_	pes of treatment you
	Yes	No	Not applicable
CNS - If yes, what information	n was needed?		
If yes, was the information ne	eed met over the	e phone?	
Yes (fully) Yes	(partly)	No	
Was further action indicated	? Yes	No	
If yes, what was the course o	f action?		
Do you have any concerns a family are at risk at getting	=		other members of t
	=		other members of t
-	endometrial (wo	omb) cancer?	other members of t
family are at risk at getting	endometrial (wo	omb) cancer?	other members of t
family are at risk at getting	endometrial (wo	omb) cancer?	other members of t

Do you need information your body and your sexu		eatment may affect your feelings abou
	Yes	No
CNS - If yes, what informa	tion was needed?	
If yes, was the information	n need met over the	e phone?
Yes (fully)	Yes (partly)	No
Was further action indicat	ed? Yes	No
If yes, what was the cours	e of action?	
Do you need information	n about your sexual	function?
	Yes	No .
CNS - If yes, what informa	tion was needed?	
If yes, was the information	n need met over the	e phone?
Yes (fully)	Yes (partly)	No
Was further action indicat	ted? Yes	No 🗌

	If yes, what was the course of action?			
10.	Do you need information about caring for yourself? (e.g. diet and appetite, exercise, problems with bowel and urinary function, support groups, complementary therapy finances, psychological support)			
	Yes	No		
	CNS - If yes, what information was needed?			
	If yes, was the information need met over th	e nhone?		
	Yes (fully) Yes (partly)	No		
	Was further action indicated? Yes	No		
	If yes, what was the course of action?			
11.	Do you have any concerns about how your	family have coped with your diagnosis?		
	Yes	No		
	CNS - If yes, what concerns were expressed?			
	If yes, was the concern dealt with over the p	hone?		
	Yes (fully) Yes (partly)	No		
	Was further action indicated? Yes	No		

	If yes, what was the course of action?
L <b>2.</b>	Is there anything else concerning you?
	Yes No
	CNS - If yes, what concerns were expressed?
	If yes, was the concern dealt with over the phone?
	Yes (fully) Yes (partly) No
	Was further action indicated? Yes No
	If yes, what was the course of action?
13.	CNS – Please arrange next appointment
- he	next telephone follow-up call will be due in months.
Dat	e of next appointment Time Time
Ple	ease check that patient has contact numbers for gynaecology oncology nursing servic
L4.	CNS – were any tests/investigation requested? Yes No
	If yes, what tests/investigations were requested?
	If yes, why were the tests /investigations requested?

15.	CNS – were any referrals made?	Yes	No
	If yes, what referrals were requested?		
	If yes, why was a referral necessary?		
16.	CNS - Additional Comments:		